Effects of Epstein-Barr virus infection on the development of multiple myeloma after liver transplantation

Science China Life Sciences

Volumn 55, Issue 8, 2012, Pages 735-743

  Zhang, YeWei ^a   Zhao, HeWei ^a   He, Xia ^a   Zheng, SuWen ^a   Wang, TaiHong ^a   Yan, DongLiang ^b   Sun, JingFeng ^a   Lu, Xiang ^c   Wen, JianFei ^a   Lau, Wan Yee ^d  

^a JIANGSU CANCER HOSPITAL   (China)

^b NANTONG UNIVERSITY   (China)

^c THE SECOND AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^d Prince of Wales Hospital   (China)

Author keywords

CD40; CD40L; EBV; liver transplantation; multiple myeloma

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND; CHEMOKINE RECEPTOR CXCR4; CXCR4 PROTEIN, HUMAN; EBV ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN BARR VIRUS; EBV-ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN-BARR VIRUS; EPSTEIN BARR VIRUS ANTIGEN; MATRIX PROTEIN;

ADOLESCENT; ADULT; APOPTOSIS; ARTICLE; CELL PROLIFERATION; EPSTEIN BARR VIRUS INFECTION; FEMALE; GENE EXPRESSION; GENETICS; HUMAN; IMMUNOLOGY; LIVER TRANSPLANTATION; MALE; METABOLISM; MIDDLE AGED; MULTIPLE MYELOMA; PATHOLOGY; TUMOR CELL LINE; VIROLOGY;

ADOLESCENT; ADULT; ANTIGENS, CD40; APOPTOSIS; CD40 LIGAND; CELL LINE, TUMOR; CELL PROLIFERATION; EPSTEIN-BARR VIRUS INFECTIONS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; FEMALE; GENE EXPRESSION; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RECEPTORS, CXCR4; VIRAL MATRIX PROTEINS; YOUNG ADULT;

HERPESVIRIDAE; HUMAN HERPESVIRUS 4;

EID: 84865821950     PISSN: 16747305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11427-012-4362-3     Document Type: Article

References (26)

1. Berenson J R, Vescio R A. HHV-8 is present in multiple myeloma patients. Blood, 1999, 93: 3157-3159.
2. Bishop G A, Hostager B S. The CD40-CD154 interaction in B cell-T cell liaisons. Cytokine Growth Factor Rev, 2003, 14: 297-309.
3. Busch L K, Bishop G A. The EBV transforming protein, LMP1, mimics and cooperates with CD40 signaling in B lymphocyte. J Immunol, 1999, 162: 2555-2561.
4. Cacciarelli T V, Green M, Jaffe R, et al. Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. Transplantation, 1998, 66: 1047-1052.
5. Challa A, Eulopulos A G, Holder M J, et al. Population depletion activates autonomous CD154-dependent survival in biopsy-like Burkitt's lymphoma cells. Blood, 2002, 99: 3411-3418.
6. Clodi K, Asgary Z, Zhao S, et al. Coexpression of CD40 and CD40 ligand in B-cell lymphoma cells. Br J Haematol, 1998, 103: 270-275.
7. Fuleihan R, Ramesh N, Horner A, et al. Cyclosporin A inhibits CD40 ligand expression in T lymphocytes. J Clin Invest, 1994, 93: 1315-1320.
8. Hallek M, Bergsagel P L, Anderson K C. Multiple myeloma: increasing evidence for a multistep transformation process. Blood, 1998, 91: 3-21.
9. Hanissian S H, Geha R S. Jak3 is associated with CD40 and is critical for CD40 induction of gene expression in B cells. Immunity, 1997, 6: 379-387.
10. Imadome K, Shirakata M, Shimizu N, et al. CD40 ligand is a critical effector of Epstein-Barr virus in host cell survival and transformation. Proc Natl Acad Sci USA, 2003, 100: 7836-7840.
11. Kaykas A, Worringer K, Sugden B. CD40 and LMP-1 both signal from lipid rafts but LMP-1 assembles a distinct, more efficient signaling complex. EMBO J, 2001, 20: 2641-2654.
12. Oh H M, Oh J M, Choi S C, et al. An efficient method for the rapid establishment of Epstein-Barr virus immortalization of human B lymphocytes. Cell Prolif, 2003, 36: 191-197.
13. Larsen C P, Elwood E T, Alexander D Z, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature, 1996, 381: 434-438.
14. Arcipowski K M, Stunz L L, Graham J P, et al. Molecular mechanisms of TNFR-associated factor 6 (TRAF6) utilization by the oncogenic viral mimic of CD40, latent membrane protein 1 (LMP1). J Biol Chem, 2011, 286: 9948-9955.
15. Wang Z, Yang S, Zhou L, et al. Specific cellular immune responses in mice immunized with DNA, adeno-associated virus and adenoviral vaccines of Epstein-Barr virus-LMP2 alone or in combination. Sci China Life Sci, 2011, 54: 263-266.
16. Mathur R K, Awasthi A, Wadhone P, et al. Reciprocal CD40 signals through p38MAPK and ERK-1/2 induce counteracting immune responses. Nat Med, 2004, 10: 540-544.
17. Mutimer D, Kaur N, Tang H, et al. Quantification of Epstein-Barr virus DNA in the blood after adult liver transplantation. Transplantation, 2000, 69: 954-959.
18. Nalesnik M A, Rao A S, Furukawa H, et al. Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients. Transplantation, 1997, 63: 1200-1205.
19. Xu H, Zhao G, Huang X, et al. CD40-expressing plasmid induces anti-CD40 antibody and enhances immune responses to DNA vaccination. J Gene Med, 2010, 12: 97-106.
20. Qi C J, Zheng L, Zhou X, et al. Cross-linking of CD40 using anti-CD40 antibody, 5C11, has different effects on XG2 multiple myeloma cells. Immunol Lett, 2004, 93: 151-158.
21. The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Hematol, 2003, 121: 749-757.
22. Tong A W, Seamour B, Chen J, et al. CD40 ligand-induced apoptosis is Fas-independent in human multiple myeloma cells. Leuk Lymphoma, 2000, 36: 543-558.
23. Uchida J, Yasui T, Takaoka-Shichijo Y, et al. Mimicry of C40 signals by EBV LMP1 in B lymphocyte responses. Science, 1999, 286: 300-303.
24. Young L S, Rickinson A B. Epstein-Barr virus: 40 years on. Nat Rev Cancer, 2004, 4: 757-768.
25. Zimber-Strobl U, Kempkes B, Marschall G, et al. Epstein-Barr virus latent membrane protein (LMP1) is not sufficient to maintain proliferation of B cells but both it and activated CD40 can prolong their survival. EMBO J, 1996, 15: 7070-7078.
26. Cao J, Shen C, Zhang J, et al. Comparison of alternative extraction methods for secretome profiling in human hepatocellular carcinoma cells. Sci China Life Sci, 2011, 54: 34-38.